ASPOFAFF :: Journal - Volume 2 :: Volume 2 - Issue 1 :: Vol 2 - Iss 1 - Short Communication - Efficacy of Aripiprazole in Bipolar Mania with Mixed Episodes, Rapid Cycling and Psychotic Symptoms


	Home


	Shopping Cart


	Contact Us


	IRBD.ORG


	EUBF.ORG

All Enquiries:: +44 (0)20 8487 1421

Search:

Advanced search

Printable version

Categories

Help

ASPOFAFF :: Journal - Volume 2 :: Volume 2 - Issue 1 :: Vol 2 - Iss 1 - Short Communication - Efficacy of Aripiprazole in Bipolar Mania with Mixed Episodes, Rapid Cycling and Psychotic Symptoms

Vol 2 - Iss 1 - Short Communication - Efficacy of Aripiprazole in Bipolar Mania with Mixed Episodes, Rapid Cycling and Psychotic Symptoms #65

Efficacy of Aripiprazole in Bipolar Mania with Mixed Episodes, Rapid Cycling and Psychotic Symptoms Jean-Yves Loze1, Robert McQuade2, William Carson3, Taro Iwamoto4, Neveen Abou-Gharbia5, Sterling Hardy6, Donald Archibald7. 1 Bristol-Myers Squibb, 3 rue Joseph Monier, BP 325, 92506 Reuil-Malmaison Cedex, France; Tel: +33 1 58 83 89 59; Fax: +33 1 58 89 59; E-mail: jean-yves.loze@bms.com 2 Otsuka America Pharmaceutical Inc., Princeton, NJ 3 Otsuka America Pharmaceutical Inc., Princeton, NJ 4Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan 5 Bristol-Myers Squibb, Lawrenceville, NJ 6 Bristol-Myers Squibb, Wallingford, CT 7 Bristol-Myers Squibb, Wallingford, CT Objective: This study demonstrates the efficacy of aripiprazole in patients with bipolar disorder, with subanalyses of patients experiencing acute mixed episodes, those with rapid cycling, and those with severe and psychotic symptoms. Methods: Data were analysed from three 3-week, double-blind, multicentre studies of patients with acute mania in bipolar I disorder. A total of 899 patients were randomised to aripiprazole (n=515) or placebo (n=384). The main outcome measure was change from baseline in Young Mania Rating Scale (YMRS). Data from the three trials were pooled and the patient population was stratified according to whether the episode was manic or mixed, the presence of rapid cycling, the severity of symptoms and the presence of psychotic symptoms. Results: Where patients were experiencing acute mixed episodes, treatment with aripiprazole resulted in significant reductions in YMRS compared to placebo (–9.7 vs –7.4, p=0.044), which was similar to reductions observed for patients with manic episodes (–10.4 vs –6.5, p<0.001). In patients with rapid cycling bipolar disorder, significant reductions in YMRS occurred with aripiprazole vs placebo (–10.6 vs –5.5, p=0.001). In patients presenting with more severe symptoms (YMRS >27), treatment with aripiprazole resulted in greater improvement vs placebo (–11.6 vs –6.8, p<0.001). Aripiprazole showed equal efficacy in patients with or without psychotic symptoms. Conclusion: In this large, pooled analysis of aripiprazole in the treatment of mania in bipolar disorder, consistently significant improvements were seen in patients with manic or mixed episodes, rapid-cycling bipolar disorder, severe symptoms and in patients with or without psychotic symptoms.

Details

Price: €0.01

Options

Quantity

Add to cart

Send to friend

Your name: *

Your e-mail: *

Recipient's e-mail: *

Send to friend

Your cart

	Cart is empty

View cart
Checkout

Authentication

Username

Password

Recover password

If Javascript is disabled in your browser click here